Celltrion brings Remsima SC biosimilar to the Netherlands
Celltrion Healthcare introduced Remsima SC in the Netherlands, the third European market where it has rolled out the biosimilar.
Celltrion Group sales company announced Thursday that it began selling Remsima SC in the country on April 27, after bringing the product to Germany and England. Remsima SC is a modified version of Remsima, which is a biosimilar referencing Janssen Biotech’s Remicade.
Biosimilars are biological pharmaceutical products that are approved based on proof that they are highly similar to a biological product that has already been approved. The drugs have no clinically meaningful differences in terms of safety or effectiveness from the original product, but they cost less.
Remsima SC won approval in Europe for treating rheumatoid arthritis. Celltrion said Remsima SC was already in high demand as many hospitals in the Netherlands already filed purchase requests, adding that the drug already received high marks from local medical and pharmaceutical experts.
BY KO JUN-TAE [firstname.lastname@example.org]